BELGRADE, Mont., Nov. 30 /PRNewswire/ -- Bacterin International, Inc. (Bacterin), a biologic company and manufacturer of elutive bioactive coatings for medical devices, has entered into a license agreement with Osteotech, Inc. . Under the agreement, Bacterin receives rights to Osteotech patents relating to flowable demineralized bone powder compositions.
The intellectual property made available through the licensure is complementary and synergistic with Bacterin’s current osteobiologic product portfolio. This relationship will assist Bacterin in developing new options for transplant recipients, ultimately improving their quality of life. “This is another significant milestone for the company,” said Jesus Hernandez, Bacterin Vice President - Biologics, who continued, “Bacterin is committed to maximizing the generous life enhancing gifts and stewardship responsibility incumbent upon the donation process. By complementing Osteotech intellectual property with proprietary Bacterin technology, we can continue to innovate within the biologics industry, providing cost effective, differentiated solutions that positively impact transplantation and patient outcomes.”
Bacterin is a company focused on improving patient care and healthcare delivery. The company has developed proprietary bioactive coating technologies suitable for a variety of medical device applications. Bacterin’s anti-infective coatings prevent microbial (biofilm) attachment and growth, thus significantly reducing bacterial adhesion associated with invasive medical devices. Aside from enhancing medical devices, it is Bacterin’s belief that allografts can also benefit from proprietary coating technologies.
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a provider of human bone and bone connective tissue for transplantation and an innovator in the development and marketing of biomaterial and implant products for musculoskeletal surgery. This is the first license agreement between the two companies.
Certain matters discussed in this press release are forward-looking statements with regards to the Company’s future plans, objectives, and anticipated performance. These forward-looking statements can generally be identified as such because the context of the statement will include words, such as Bacterin International, Inc. “expects,” “should,” “believes,” “anticipates” or words of similar import. Bacterin International, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions; the Company cannot give any assurance that the expectations will be attained. These forward-looking statements are only made as of the date of this press release; Bacterin International, Inc. undertakes no obligation to publicly update this information.
For more information regarding Bacterin, or this press release, please visit www.bacterin.com.
Bacterin International, Inc.
CONTACT: Guy Cook, President, GCook@bacterin.com, or Investors, MollyMason, mmason@bacterin.com, both of Bacterin International, Inc.,+1-406-388-0480
Web site: http://www.bacterin.com/
